Penn Spinout Interius Therapeutics To Be Acquired by Kite Therapeutics for $350M
Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics .
Capstan Therapeutics Acquired by AbbVie for $2.1B
AbbVie acquired Capstan, including its lead asset CPTX2309.
App that uses AI to boost caregiving for seniors wins PCI pitch competition at Philly Tech Week
PCI, Pennovation Works and Philadelphia Alliance for Capital & Technologies (PACT) hosted the “Innovate & Inspire: Research Panel & Pitch Competition” in May.
Dr. Jim Wilson’s Gene Therapy Work with Gemma Biotherapeutics Profiled by the Philadelphia Inquirer
Gemma Biotherapeutics was co-founded in 2024 by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Cerespectus and Vasowatch Join HiveBio’s Inaugural Cohort
HiveBio has selected its inaugural cohort of underrepresented biotech founders.
Cerespectus Accepted into Science Center’s Capital Readiness Program
Cerespectus was co-founded by Bryan Pukenas, MD, Associate Professor of Radiology in Penn Medicine.
MavriX Bio Announces FDA Clearance for Gene Therapy Trial
MavriX will initiate a clinical trial of a gene therapy for Angelman syndrome.
Capstan Therapeutics Begins Phase 1 Trial of CAR-T Therapy for Autoimmune Disease
Capstan Therapeutics, a biotechnology company spun out of Penn, has initiated its Phase 1 trial of an in vivo CAR-T therapy.
REGENXBIO’s Gene Therapy Updates for Hunter Syndrome and DMD
REGENXBIO was co-founded by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Vivodyne Raises $40 Million to Advance Human Tissue Testing Platform
Vivodyne was co-founded by Dan Huh, PhD, Professor of Bioengineering in Penn Engineering and CEO Andrei Georgescu.,